714 related articles for article (PubMed ID: 30064502)
1. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
3. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
[TBL] [Abstract][Full Text] [Related]
4. Protocol for a systematic review and individual participant data meta-analysis of B-type natriuretic peptide-guided therapy for heart failure.
Pufulete M; Higgins JP; Rogers CA; Dreyer L; Hollingworth W; Dayer M; Nightingale A; McDonagh T; Reeves BC
Syst Rev; 2014 May; 3():41. PubMed ID: 24886933
[TBL] [Abstract][Full Text] [Related]
5. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
[TBL] [Abstract][Full Text] [Related]
6. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials.
Li P; Luo Y; Chen YM
Heart Lung Circ; 2013 Oct; 22(10):852-60. PubMed ID: 23602555
[TBL] [Abstract][Full Text] [Related]
7. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.
Savarese G; Trimarco B; Dellegrottaglie S; Prastaro M; Gambardella F; Rengo G; Leosco D; Perrone-Filardi P
PLoS One; 2013; 8(3):e58287. PubMed ID: 23472172
[TBL] [Abstract][Full Text] [Related]
8. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis.
Khan MS; Siddiqi TJ; Usman MS; Sreenivasan J; Fugar S; Riaz H; Murad MH; Mookadam F; Figueredo VM
Int J Cardiol; 2018 Jul; 263():80-87. PubMed ID: 29685696
[TBL] [Abstract][Full Text] [Related]
9. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
Pfisterer M; Buser P; Rickli H; Gutmann M; Erne P; Rickenbacher P; Vuillomenet A; Jeker U; Dubach P; Beer H; Yoon SI; Suter T; Osterhues HH; Schieber MM; Hilti P; Schindler R; Brunner-La Rocca HP;
JAMA; 2009 Jan; 301(4):383-92. PubMed ID: 19176440
[TBL] [Abstract][Full Text] [Related]
10. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.
Porapakkham P; Porapakkham P; Zimmet H; Billah B; Krum H
Arch Intern Med; 2010 Mar; 170(6):507-14. PubMed ID: 20308637
[TBL] [Abstract][Full Text] [Related]
11. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
De Vecchis R; Esposito C; Di Biase G; Ariano C; Giasi A; Cioppa C
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):122-34. PubMed ID: 24522083
[TBL] [Abstract][Full Text] [Related]
12. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
14. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure.
Mohiuddin S; Reeves B; Pufulete M; Maishman R; Dayer M; Macleod J; McDonagh T; Purdy S; Rogers C; Hollingworth W
BMJ Open; 2016 Dec; 6(12):e014010. PubMed ID: 28031211
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis.
Curtain JP; Lee MMY; McMurray JJ; Gardner RS; Petrie MC; Jhund PS
Heart; 2023 May; 109(11):823-831. PubMed ID: 36522146
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Prognostic Significance of Plasma B-Type Natriuretic Peptide Level in Patients With Acute Heart Failure With Reduced, Mid-Range, and Preserved Ejection Fractions.
Hamatani Y; Nagai T; Shiraishi Y; Kohsaka S; Nakai M; Nishimura K; Kohno T; Nagatomo Y; Asaumi Y; Goda A; Mizuno A; Yasuda S; Ogawa H; Yoshikawa T; Anzai T;
Am J Cardiol; 2018 Mar; 121(6):731-738. PubMed ID: 29394996
[TBL] [Abstract][Full Text] [Related]
17. Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials.
Taylor RS; Walker S; Smart NA; Piepoli MF; Warren FC; Ciani O; O'Connor C; Whellan D; Keteyian SJ; Coats A; Davos CH; Dalal HM; Dracup K; Evangelista L; Jolly K; Myers J; McKelvie RS; Nilsson BB; Passino C; Witham MD; Yeh GY; Zwisler AO;
Eur J Heart Fail; 2018 Dec; 20(12):1735-1743. PubMed ID: 30255969
[TBL] [Abstract][Full Text] [Related]
18. Natriuretic peptide-guided treatment for heart failure: a systematic review and meta-analysis.
McLellan J; Bankhead CR; Oke JL; Hobbs FDR; Taylor CJ; Perera R
BMJ Evid Based Med; 2020 Feb; 25(1):33-37. PubMed ID: 31326896
[TBL] [Abstract][Full Text] [Related]
19. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
